ATE123218T1 - Pharmazeutische ionenaustauscherharzzusammensetzung. - Google Patents
Pharmazeutische ionenaustauscherharzzusammensetzung.Info
- Publication number
- ATE123218T1 ATE123218T1 AT89311701T AT89311701T ATE123218T1 AT E123218 T1 ATE123218 T1 AT E123218T1 AT 89311701 T AT89311701 T AT 89311701T AT 89311701 T AT89311701 T AT 89311701T AT E123218 T1 ATE123218 T1 AT E123218T1
- Authority
- AT
- Austria
- Prior art keywords
- ion exchange
- exchange resin
- resin composition
- alcohol
- water
- Prior art date
Links
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003456 ion exchange resin Substances 0.000 title abstract 3
- 229920003303 ion-exchange polymer Polymers 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 238000005469 granulation Methods 0.000 abstract 2
- 230000003179 granulation Effects 0.000 abstract 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 abstract 1
- 229960004503 metoclopramide Drugs 0.000 abstract 1
- 229960005181 morphine Drugs 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 1
- 229960002675 xylitol Drugs 0.000 abstract 1
- 235000010447 xylitol Nutrition 0.000 abstract 1
- 239000000811 xylitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888826407A GB8826407D0 (en) | 1988-11-11 | 1988-11-11 | Pharmaceutical ion exchange resin composition |
| GB888828592A GB8828592D0 (en) | 1988-12-07 | 1988-12-07 | Pharmaceutical ion exchange resin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE123218T1 true ATE123218T1 (de) | 1995-06-15 |
Family
ID=26294609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89311701T ATE123218T1 (de) | 1988-11-11 | 1989-11-10 | Pharmazeutische ionenaustauscherharzzusammensetzung. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5071646A (de) |
| EP (1) | EP0368682B1 (de) |
| JP (1) | JP2825202B2 (de) |
| AT (1) | ATE123218T1 (de) |
| AU (1) | AU621949B2 (de) |
| CA (1) | CA2002492A1 (de) |
| DE (1) | DE68922894T2 (de) |
| DK (1) | DK175154B1 (de) |
| ES (1) | ES2075061T3 (de) |
| GB (1) | GB2225941B (de) |
| IE (1) | IE893625L (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9003903D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | New pharmaceutical formulations |
| SE9003904D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | Method for the manufacture of a pharmaceutical dosage form |
| US5275820A (en) * | 1990-12-27 | 1994-01-04 | Allergan, Inc. | Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles |
| US5840339A (en) * | 1991-07-30 | 1998-11-24 | Kunin; Robert | Blood cholesterol reducing pharmaceutical composition |
| SE9103110D0 (sv) * | 1991-10-24 | 1991-10-24 | Kabi Pharmacia Ab | New drug formulation |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5296228A (en) * | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
| US5350584A (en) * | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
| US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| USRE39300E1 (en) | 1993-01-28 | 2006-09-19 | Virginia Commonwealth University Medical College Of Virginia | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
| NZ260408A (en) * | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US7740881B1 (en) | 1993-07-01 | 2010-06-22 | Purdue Pharma Lp | Method of treating humans with opioid formulations having extended controlled release |
| US5879705A (en) * | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
| US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| GB9422154D0 (en) * | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
| GB9517883D0 (en) * | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| AU1970797A (en) * | 1997-02-25 | 1998-09-09 | Procter & Gamble Company, The | Wet granulating method |
| US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
| TR200001942T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid agonist/antagonist kombinasyonlar |
| US6806294B2 (en) | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
| US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
| US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
| EP2295043A1 (de) | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Hydrocodon-Formulierungen mit gesteuerter Freisetzung |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| SI2283842T1 (sl) | 2000-02-08 | 2015-07-31 | Euro-Celtique S.A. | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| WO2001062236A2 (en) * | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| US6855721B1 (en) | 2000-07-28 | 2005-02-15 | Indevus Pharmaceuticals, Inc. | Methods and compositions for alleviating stuttering |
| AU2002227383B2 (en) | 2000-10-30 | 2004-07-08 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| EP1387673B1 (de) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Opioid enthaltende arzneiform gegen missbrauch |
| DK1416842T3 (da) | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
| ES2326794T3 (es) | 2001-08-06 | 2009-10-20 | Euro-Celtique S.A. | Formulaciones de agonistas opioides con antagonista liberable y secuestrado. |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
| US20030099711A1 (en) * | 2001-08-29 | 2003-05-29 | David Meadows | Sustained release preparations |
| US20030180249A1 (en) * | 2002-03-18 | 2003-09-25 | Khanna Satish Chandra | Dosage forms for hygroscopic active ingredients |
| LT2425821T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
| SI1551372T1 (en) | 2002-09-20 | 2018-08-31 | Alpharma Pharmaceuticals Llc | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES |
| US6893660B2 (en) * | 2002-11-21 | 2005-05-17 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions without a stabilizer |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
| JP2007504239A (ja) * | 2003-09-03 | 2007-03-01 | マリンクロッド・インコーポレイテッド | 顆粒状持続放出製剤およびその製造 |
| US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
| JP2007534771A (ja) | 2004-04-27 | 2007-11-29 | メディシノバ，インコーポレーテッド | 炎症性疾患の治療におけるフェノキシアルキルカルボン酸誘導体 |
| WO2005110412A1 (en) * | 2004-05-14 | 2005-11-24 | Green Cross Corp. | Neuroprotective properties of dextrorotatory morphinans |
| EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
| WO2006061700A2 (en) * | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Rapid disintegrating taste masked compositions and a process for its preparations |
| US20070036843A1 (en) * | 2005-01-28 | 2007-02-15 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
| EP1702558A1 (de) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
| US8343546B2 (en) * | 2005-09-13 | 2013-01-01 | Coating Place, Inc. | Ion exchange resin treated to control swelling |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| ATE536867T1 (de) | 2006-03-16 | 2011-12-15 | Tris Pharma Inc | Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen |
| SI2484346T1 (sl) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| WO2009088385A1 (en) * | 2008-01-04 | 2009-07-16 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
| PL2405915T3 (pl) | 2009-03-10 | 2019-05-31 | Euro Celtique Sa | Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson |
| WO2010132662A1 (en) * | 2009-05-13 | 2010-11-18 | Relypsa, Inc. | Powder formulations of potassium-binding active agents |
| JP2013119550A (ja) | 2011-12-08 | 2013-06-17 | Medicinova Inc | 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法 |
| US8962687B2 (en) | 2012-12-05 | 2015-02-24 | Medicinova, Inc. | Method of treating liver disorders |
| WO2014167440A1 (en) * | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof |
| KR20160034352A (ko) | 2013-07-23 | 2016-03-29 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
| WO2015013395A1 (en) | 2013-07-25 | 2015-01-29 | Medicinova, Inc. | Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels |
| US9346754B2 (en) | 2014-05-08 | 2016-05-24 | Medicinova, Inc. | Method of treating advanced non-alcoholic steatohepatitis |
| US20150321989A1 (en) | 2014-05-08 | 2015-11-12 | Medicinova, Inc. | Method of treating idiopathic pulmonary fibrosis |
| CA2950909C (en) | 2014-06-02 | 2023-03-28 | Medicinova, Inc. | Method of inhibiting or treating fibrosis |
| US10258611B2 (en) | 2014-11-26 | 2019-04-16 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| CA3034895A1 (en) | 2016-08-26 | 2018-03-01 | Exciva Ug (Haftungsbeschrankt) | Compositions and methods thereof |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| CN117320701A (zh) | 2021-05-28 | 2023-12-29 | 美迪诺亚公司 | 一种降低肝脏中甘油三酯合成的方法 |
| CN121038779A (zh) | 2023-02-03 | 2025-11-28 | 特瑞斯制药公司 | 每晚一次的低钠羟丁酸盐组合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791281A (en) * | 1955-01-13 | 1958-02-26 | Genatosan Ltd | Pharmaceutical products |
| GB822728A (en) * | 1955-07-14 | 1959-10-28 | Pfizer & Co C | Vitamin products and process of preparing same |
| GB835932A (en) * | 1956-03-27 | 1960-05-25 | Ciba Ltd | Process for the manufacture of therapeutic tablet granulations |
| FR792M (de) * | 1959-11-13 | 1961-09-11 | ||
| US3138525A (en) * | 1961-06-16 | 1964-06-23 | Hoffmann La Roche | Castor wax-amprotropine-resin compositions |
| GB982150A (en) * | 1961-09-29 | 1965-02-03 | Glaxo Group Ltd | Therapeutic resin complexes |
| NL295533A (de) * | 1962-08-06 | |||
| DE2706660A1 (de) * | 1977-02-17 | 1978-08-24 | Merck Patent Gmbh | Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung |
| GB1566609A (en) * | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
| US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| DE2929456A1 (de) * | 1979-07-20 | 1981-02-05 | Lentia Gmbh | Zusammensetzung mit verlaengerter broncholytischer und tokolytischer wirksamkeit, ein verfahren zu deren herstellung und broncholytisch und tokolytisch wirkendes mittel |
| US4404346A (en) * | 1980-08-05 | 1983-09-13 | Rohm And Haas Company | Production of powdered resin and the powdered resin so produced |
| US4369175A (en) * | 1981-07-27 | 1983-01-18 | Ciba-Geigy Corporation | Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them |
| CH655507B (de) * | 1983-01-12 | 1986-04-30 | ||
| US4847362A (en) * | 1985-02-01 | 1989-07-11 | New York University | Method for purifying antihemophilic factor |
| EP0200252B1 (de) * | 1985-05-02 | 1999-03-10 | Yamanouchi Europe B.V. | Trimethoprim und ein Sulfonamid enthaltende Tabletten |
| EP0199855A1 (de) * | 1985-05-02 | 1986-11-05 | Gist-Brocades N.V. | Trimethoprim und ein Sulfonamid enthaltende Tabletten |
| US4748361A (en) * | 1985-12-05 | 1988-05-31 | Mitsubishi Kinzoku Kabushiki Kaisha | Permanent magnet electric motor |
| US4788055A (en) * | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
| DD249634B1 (de) * | 1986-06-04 | 1988-09-21 | Bitterfeld Chemie | Cholesterolsenkendes mittel und verfahren zu seiner herstellung |
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
-
1989
- 1989-11-08 CA CA002002492A patent/CA2002492A1/en not_active Abandoned
- 1989-11-09 US US07/434,416 patent/US5071646A/en not_active Expired - Lifetime
- 1989-11-09 JP JP1290147A patent/JP2825202B2/ja not_active Expired - Lifetime
- 1989-11-09 AU AU44530/89A patent/AU621949B2/en not_active Expired
- 1989-11-10 DE DE68922894T patent/DE68922894T2/de not_active Expired - Lifetime
- 1989-11-10 GB GB8925492A patent/GB2225941B/en not_active Revoked
- 1989-11-10 AT AT89311701T patent/ATE123218T1/de not_active IP Right Cessation
- 1989-11-10 ES ES89311701T patent/ES2075061T3/es not_active Expired - Lifetime
- 1989-11-10 EP EP89311701A patent/EP0368682B1/de not_active Expired - Lifetime
- 1989-11-10 IE IE893625A patent/IE893625L/xx not_active IP Right Cessation
- 1989-11-10 DK DK198905645A patent/DK175154B1/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02243618A (ja) | 1990-09-27 |
| AU621949B2 (en) | 1992-03-26 |
| AU4453089A (en) | 1990-05-17 |
| EP0368682B1 (de) | 1995-05-31 |
| CA2002492A1 (en) | 1990-05-11 |
| DK564589D0 (da) | 1989-11-10 |
| DK175154B1 (da) | 2004-06-21 |
| GB2225941B (en) | 1992-12-09 |
| GB8925492D0 (en) | 1989-12-28 |
| DK564589A (da) | 1990-05-12 |
| GB2225941A (en) | 1990-06-20 |
| ES2075061T3 (es) | 1995-10-01 |
| DE68922894T2 (de) | 1996-01-11 |
| IE893625L (en) | 1990-05-11 |
| US5071646A (en) | 1991-12-10 |
| EP0368682A1 (de) | 1990-05-16 |
| JP2825202B2 (ja) | 1998-11-18 |
| DE68922894D1 (de) | 1995-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68922894D1 (de) | Pharmazeutische Ionenaustauscherharzzusammensetzung. | |
| AU625467B2 (en) | Pesticidal active ingredient concentrates and the preparation thereof | |
| GB9018940D0 (en) | Dosage device and preparation and use thereof | |
| DE69000881D1 (de) | 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe. | |
| DK473889A (da) | Granula | |
| IE891527L (en) | Drug absorbates | |
| EP0724885A4 (de) | Pernasale zusammensetzung und diese enthaltende pernasale zubereitung | |
| DK214689A (da) | Farmaceutiske midler | |
| IE882391L (en) | Pad printing process | |
| MX9203555A (es) | Sistema intravenoso para administrar un agente benefico y/o farmaco. | |
| FI891865A7 (fi) | Atselastiinia sisältäviä lääkkeitä, joista vaikuttava aine vapautuu säädellysti | |
| AU571205B2 (en) | Pyrethroid pharmaceutical composition | |
| AU570446B2 (en) | Dipyridamole controlled release compositon | |
| ATA124091A (de) | Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz | |
| KR960003718A (ko) | 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용 | |
| Orlova et al. | Toxicity of an original antiemetic preparation dimetpramid | |
| ATE78684T1 (de) | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. | |
| TH20468A (th) | สารผสมของยาระงับกรดชนิดของเหลว | |
| BR1101024A (pt) | Sistema terapêutico de liberação controlada para formulações relacionadas a formas farmacêuticas lìquidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |